125 related articles for article (PubMed ID: 31350703)
1. Involvement of the MDR1 gene and glycolipids in anticancer drug-resistance of human ovarian carcinoma-derived cells.
Tanaka K; Kiguchi K; Mikami M; Aoki D; Iwamori M
Hum Cell; 2019 Oct; 32(4):447-452. PubMed ID: 31350703
[TBL] [Abstract][Full Text] [Related]
2. Possible involvement of glycolipids in anticancer drug resistance of human ovarian serous carcinoma-derived cells.
Tanaka K; Takada H; Isonishi S; Aoki D; Mikami M; Kiguchi K; Iwamori M
J Biochem; 2012 Dec; 152(6):587-94. PubMed ID: 23038675
[TBL] [Abstract][Full Text] [Related]
3. Characteristic expression of Lewis-antigenic glycolipids in human ovarian carcinoma-derived cells with anticancer drug-resistance.
Iwamori M; Iwamori Y; Kubushiro K; Ishiwata I; Kiguchi K
J Biochem; 2007 Mar; 141(3):309-17. PubMed ID: 17190787
[TBL] [Abstract][Full Text] [Related]
4. Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Yamamoto K; Kikuchi Y; Kudoh K; Nagata I
J Cancer Res Clin Oncol; 2000 Mar; 126(3):168-72. PubMed ID: 10741911
[TBL] [Abstract][Full Text] [Related]
5. Characteristic expression of globotriaosyl ceramide in human ovarian carcinoma-derived cells with anticancer drug resistance.
Kiguchi K; Iwamori Y; Suzuki N; Kobayashi Y; Ishizuka B; Ishiwata I; Kita T; Kikuchi Y; Iwamori M
Cancer Sci; 2006 Dec; 97(12):1321-6. PubMed ID: 16995873
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
7. MDR1 and MDR3 genes and drug resistance to cisplatin of ovarian cancer cells.
Ren L; Xiao L; Hu J
J Huazhong Univ Sci Technolog Med Sci; 2007 Dec; 27(6):721-4. PubMed ID: 18231753
[TBL] [Abstract][Full Text] [Related]
8. Induction of thymidine phosphorylase expression by Taxol does not enhance Furtulon sensitivity in a cisplatin-resistant human ovarian carcinoma cell line.
Hata K; Osaki M; Kanasaki H; Nakayama K; Fujiwaki R; Ito H; Miyazaki K
Anticancer Res; 2003; 23(2B):1525-31. PubMed ID: 12820419
[TBL] [Abstract][Full Text] [Related]
9. Increase in docetaxel-resistance of ovarian carcinoma-derived RMG-1 cells with enhanced expression of Lewis Y antigen.
Zhang F; Liu J; Lin B; Liu Q; Zhao Y; Zhu L; Hao Y; Zhang S; Iwamori M
Int J Mol Sci; 2011; 12(11):7323-34. PubMed ID: 22174601
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of pregnane X receptor pathway contributes to the cell growth inhibition and apoptosis of anticancer agents in ovarian cancer cells.
Masuyama H; Nakamura K; Nobumoto E; Hiramatsu Y
Int J Oncol; 2016 Sep; 49(3):1211-20. PubMed ID: 27572875
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
Itamochi H; Kigawa J; Sultana H; Iba T; Akeshima R; Kamazawa S; Kanamori Y; Terakawa N
Jpn J Cancer Res; 2002 Jun; 93(6):723-8. PubMed ID: 12079522
[TBL] [Abstract][Full Text] [Related]
12. Regulation of multidrug resistance 1 expression by CDX2 in ovarian mucinous adenocarcinoma.
Koh I; Hinoi T; Sentani K; Hirata E; Nosaka S; Niitsu H; Miguchi M; Adachi T; Yasui W; Ohdan H; Kudo Y
Cancer Med; 2016 Jul; 5(7):1546-55. PubMed ID: 27060927
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines.
Schöndorf T; Neumann R; Benz C; Becker M; Riffelmann M; Göhring UJ; Sartorius J; von König CH; Breidenbach M; Valter MM; Hoopmann M; Di Nicolantonio F; Kurbacher CM
Recent Results Cancer Res; 2003; 161():111-6. PubMed ID: 12528803
[TBL] [Abstract][Full Text] [Related]
14. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
15. AS602801 Sensitizes Ovarian Cancer Stem Cells to Paclitaxel by Down-regulating MDR1.
Yamamoto M; Suzuki S; Togashi K; Sanomachi T; Seino S; Kitanaka C; Okada M
Anticancer Res; 2019 Feb; 39(2):609-617. PubMed ID: 30711936
[TBL] [Abstract][Full Text] [Related]
16. Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin.
Kobayashi Y; Seino K; Hosonuma S; Ohara T; Itamochi H; Isonishi S; Kita T; Wada H; Kojo S; Kiguchi K
Gynecol Oncol; 2011 May; 121(2):390-4. PubMed ID: 21272926
[TBL] [Abstract][Full Text] [Related]
17. PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer.
Risnayanti C; Jang YS; Lee J; Ahn HJ
Sci Rep; 2018 May; 8(1):7498. PubMed ID: 29760419
[TBL] [Abstract][Full Text] [Related]
18. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X
J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179
[TBL] [Abstract][Full Text] [Related]
19. Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein.
Stordal B; Hamon M; McEneaney V; Roche S; Gillet JP; O'Leary JJ; Gottesman M; Clynes M
PLoS One; 2012; 7(7):e40717. PubMed ID: 22792399
[TBL] [Abstract][Full Text] [Related]
20. Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer.
Hille S; Rein DT; Riffelmann M; Neumann R; Sartorius J; Pfützner A; Kurbacher CM; Schöndorf T; Breidenbach M
Anticancer Drugs; 2006 Oct; 17(9):1041-4. PubMed ID: 17001177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
